PharmaKB logo
Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
AboutPricing
Drug ReportsRisedronate
Risedronic acid
Actonel, Atelvia, Risedronate (risedronic acid) is a small molecule pharmaceutical. Risedronic acid was first approved as Actonel on 1998-03-27. The pharmaceutical is active against farnesyl pyrophosphate synthase.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Plot placeholder
Mock data
Subscribe for the real data
Commercial
Therapeutic Areas
No data
Trade Name
FDA
EMA
Actonel, Atelvia, Risedronate (discontinued: Actonel, Risedronate)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Risedronate sodium
Tradename
Company
Number
Date
Products
ATELVIAAllerganN-022560 RX2010-10-08
1 products, RLD, RS
ACTONELAllerganN-020835 RX2002-05-25
2 products, RLD, RS
Show 1 discontinued
Calcium carbonate
+
Risedronate sodium
Tradename
Company
Number
Date
Products
ACTONEL WITH CALCIUM (COPACKAGED)Warner ChilcottN-021823 DISCN2005-08-12
1 products, RLD
Hide discontinued
Labels
FDA
EMA
Brand Name
Status
Last Update
actonelNew Drug Application2023-10-01
atelviaNew Drug Application2023-10-20
risedronate sodiumANDA2024-11-22
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
postmenopausal osteoporosisEFO_0003854D015663—
extramammary paget disease—D010145—
Agency Specific
FDA
EMA
No data
Patent Expiration
Patent
Expires
Flag
FDA Information
Risedronate Sodium, Atelvia, Apil
76454592028-01-09DPU-662
76454602028-01-09DPU-662
82469892026-01-16DP
ATC Codes
M: Musculo-skeletal system drugs
— M05: Drugs for treatment of bone diseases
— M05B: Drugs affecting bone structure and mineralization
— M05BA: Bisphosphonate drugs affecting bone structure and mineralization
— M05BA07: Risedronic acid
— M05BB: Bisphosphonates, combinations affecting bone structure and mineralization
— M05BB02: Risedronic acid and calcium, sequential
— M05BB04: Risedronic acid, calcium and colecalciferol, sequential
— M05BB07: Risedronic acid and colecalciferol
HCPCS
No data
Clinical
Clinical Trials
110 clinical trials
View more details
Plot placeholder
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
OsteoporosisD010024HP_0000939M81.0——22—4
Postmenopausal osteoporosisD015663EFO_0003854———11—2
Spinal fracturesD016103EFO_0003902S12——11—2
Hip fracturesD006620EFO_0003964S72.00———1—1
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Back painD001416HP_0003418M54——1——1
Bone fracturesD050723EFO_0003931T14.8——1——1
Indications Phases 2
No data
Indications Phases 1
No data
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameRisedronic acid
INNrisedronic acid
Description
Risedronic acid is a member of pyridines.
Classification
Small molecule
Drug classcalcium metabolism regulators
Image (chem structure or protein)Loading
Structure (InChI/SMILES or Protein Sequence)
O=P(O)(O)C(O)(Cc1cccnc1)P(=O)(O)O
Identifiers
PDB—
CAS-ID105462-24-6
RxCUI—
ChEMBL IDCHEMBL923
ChEBI ID8869
PubChem CID5245
DrugBankDB00884
UNII IDKM2Z91756Z (ChemIDplus, GSRS)
Target
Agency Approved
FDPS
FDPS
Organism
Homo sapiens
Gene name
FDPS
Gene synonyms
FPS, KIAA1293
NCBI Gene ID
Protein name
farnesyl pyrophosphate synthase
Protein synonyms
(2E,6E)-farnesyl diphosphate synthase, Dimethylallyltranstransferase, Farnesyl diphosphate synthase, farnesyl pyrophosphate synthetase, dimethylallyltranstransferase, geranyltranstransferase, FPP synthase, FPP synthetase, Geranyltranstransferase
Uniprot ID
Mouse ortholog
Fdps (110196)
farnesyl pyrophosphate synthase (Q920E5)
Alternate
No data
Variants
No data
Financial
Revenue by drug
$
€
£
â‚£
No data
Estimated US medical usage
Risedronic acid
+
Calcium carbonate
+
Risedronate
Total medical expenditures per year (USD, in millions)
Plot placeholder
Mock data
Subscribe for the real data
Number of persons purchased
Plot placeholder
Mock data
Subscribe for the real data
Number of purchases
Plot placeholder
Mock data
Subscribe for the real data
Refill frequency
Plot placeholder
Mock data
Subscribe for the real data
Price per prescription (USD)
Plot placeholder
Mock data
Subscribe for the real data
Risedronic acid
+
Risedronate
Total medical expenditures per year (USD, in millions)
Plot placeholder
Mock data
Subscribe for the real data
Number of persons purchased
Plot placeholder
Mock data
Subscribe for the real data
Number of purchases
Plot placeholder
Mock data
Subscribe for the real data
Refill frequency
Plot placeholder
Mock data
Subscribe for the real data
Price per prescription (USD)
Plot placeholder
Mock data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Plot placeholder
Mock data
Subscribe for the real data
Additional graphs summarizing 6,825 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Plot placeholder
Mock data
Subscribe for the real data
13,188 adverse events reported
View more details
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use